Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Beigene Ltd Ads (BGNE)

$198.25 1.85 (0.94%)

17:42 EST BGNE Stock Quote Delayed 15 Minutes

Volume:

Previous Close $198.25

Market Cap 10.66B

PE Ratio -66.30

EPS -2.99

Volume (Avg. Vol.) 518,700

Day's Range 194.83 - 204.00

52-Week Range 108.00 - 204.00

Dividend & Yield N/A (N/A)

BGNE Stock Predictions, Articles, and Beigene Ltd Ads News

From InvestorPlace
From the Web

5 Cheap Chinese Stocks to Buy Now

By Harriet Lefton, Writer, TipRanks Jul 5, 2018

With all of the trade war headlines, investors might be tempted to stay away from Chinese stocks, but China is still a massive, growing market and these stocks can be bought at a massive discount.

Week In Review: BeiGene's BTK Inhibitor Approved In US And China Approval For PD-1 Expected In Two Months

From Talk Markets Nov 16, 2019

Beijing's BeiGene had an outstanding week: its BTK drug, Brukinsa™, was approved for US use to treat mantle cell lymphoma, and its PD-1 candidate is poised for China approval before the end of the year to treat classical Hodgkin’s lymphoma.

Best & Worst Performing Mid Cap Stocks for November 15, 2019

From StockNews.com Nov 15, 2019

BGNE – BGNE leads the way today as the best performing mid cap stock, closing up 37.02%.

10 Biggest Price Target Changes For Friday

From Benzinga Nov 15, 2019

Raymond James raised Walmart Inc (NYSE: WMT) price target from $120 to $130. Walmart shares closed at $120.65 on Thursday. UBS cut the price target for Farfetch Ltd (NYSE:...

35 Stocks Moving in Friday's Pre-Market Session

From Benzinga Nov 15, 2019

Gainers Senmiao Technology Ltd (NASDAQ: AIHS) shares rose 93.2% to $0.81 in pre-market trading after the company reported Q2 EPS and sales results up from last year. Plus...

The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval

From Benzinga Nov 15, 2019

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ...

Best & Worst Performing Mid Cap Stocks for November 14, 2019

From StockNews.com Nov 14, 2019

BGNE – BGNE leads the way today as the best performing mid cap stock, closing up 37.02%.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!